

## 2026 MATWIN award for KyDo Therapeutics

- **KyDo has been awarded with the 2026 MATWIN price for the best drug-based innovation project in oncology.**
- **KyDo's lead program consists of novel covalent-allosteric inhibitors with the potential to become best-in-class oncology drugs.**

*May 27th, 2026, Dortmund, Germany – KyDo Therapeutics GmbH (KyDo), a preclinical-stage biotechnology company committed to developing novel covalent-allosteric small molecule inhibitors with the potential to become best-in-class oncology drugs, announced today the reception of the 2026 MATWIN award for the best drug-based innovation project in oncology. The selection is made once a year by the MATWIN board comprising oncology experts from 9 different pharmaceutical companies.*

The Dortmund-based company was jointly founded by Lead Discovery Center GmbH (LDC), together with scientists from the TU Dortmund University. The core technology of KyDo was originally developed by Prof. Daniel Rauh, and was subsequently advanced into a drug discovery program through a collaboration between LDC, TU Dortmund University, Taros Chemicals GmbH & Co. KG, and the Leibniz Institute IfADo.

Led by an experienced team of managers and advisors, as well as by a robust investment syndicate, KyDo is well positioned to deliver groundbreaking science with the aim of improving patient care. KyDo announced today the reception of the 2026 MATWIN award for the best drug-based innovation project in oncology. The MATWIN award is granted once a year at the MEET2WIN convention held in Bordeaux, and is the result of a highly competitive selection process by the MATWIN board members. MATWIN, a unique open-innovation platform in Europe, has been bringing together the academic, industrial, and entrepreneurial world for 16 years, with the goal to accelerate the transformation of research projects into concrete clinical solutions. This model is powered by the commitment of 9 pharmaceutical company partners, the MATWIN board members, which directly involve their R&D world executive decision-makers to evaluate and support innovation with a high medical impact in the field.

“This is a great honor for the KyDo-team and we thank the MATWIN organizers and coaches for supporting us over the last months,” said Matthias Stein-Gerlach, CEO of KyDo. “We are excited about the positive vote of such an esteemed collection of pharmaceutical oncology experts underlining the potential of KyDo's best-in-class compounds to address unmet therapeutic needs in cancer.”

###

### **About KyDo Therapeutics**

KyDo Therapeutics (KyDo), based in Dortmund, Germany, was jointly founded by Lead Discovery Center GmbH (LDC), together with scientists from the Rauh Lab at TU Dortmund University. KyDo successfully concluded a seed financing round in 2025 spearheaded by I&I Bio together with KHAN-II, and with notable participation of VORMvc, and TU capital. KyDo's covalent-allosteric drug discovery platform addresses highly relevant cancer targets with novel precision medicine that bear a huge potential to improve the efficacy, minimize the side effects and enable completely new combination therapies that are urgently needed.

Further information at: <https://kydo-tx.com>

## **About MATWIN**

MATWIN, a 100% subsidiary of Unicancer, is a French open-innovation platform dedicated exclusively to oncology. For the past 16 years, the platform has offered various support actions (expertise, accelerator programs, events, etc.) to boost the development of innovative cancer-related projects. Its activities are backed by a longstanding partnership with 9 global pharma companies committed to advancing impactful innovation in oncology (Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Exact Sciences, MSD, Pierre Fabre, Pfizer, Sanofi, Servier). Since 2021, MATWIN also coordinates the OncoSTART consortium dedicated to oncology entrepreneurship, which brings together 14 expert organizations in cancer research and innovation.

Further information at: <https://matwin.fr/>

###

### **Contact:**

info@kydo-tx.com

###